Table 1.
Baseline clinical and therapeutic characteristics of studied patients (n = 32)
| Total (n = 32) | CGC1 (ALL) (n = 12) | CyGC2 (NHL) (n = 20) | P ^ 1 vs. 2 | |
|---|---|---|---|---|
|
Age (yrs.)* |
38.4 ± 18.7 |
34.3 ± 21.5 |
40.8 ± 16.7 |
0.35 |
|
Gender, n (%) |
|
|
|
|
| Male |
15 (46.8) |
6 (50) |
9 (45) |
0.82 |
| Female |
17 (53.2) |
6 (50) |
11 (55) |
0.76 |
|
BMI† |
|
|
|
|
| <20 |
2 (6.3) |
1 (8.3) |
1 (5) |
0.88 |
| 20-24.9 |
7 (21.9) |
2 (16.7) |
5 (25) |
0.45 |
| 25 – 29.9 |
14 (43.7) |
4 (33.3) |
10 (50) |
0.23 |
| ≥30 |
9 (28.1) |
5 (41.7) |
4 (20) |
0.19 |
|
W/H ratio, n (%) |
|
|
|
|
| ≥0.8 |
29 (90.6) |
9 (75) |
20 (100) |
0.81 |
| <0.8 |
3 (9.4) |
3 (25) |
0 |
0.12 |
|
PAD mg/patient |
|
|
|
|
| 8 weeks |
- |
4,200 |
1,500 |
- |
| 12 weeks |
- |
- |
2,500 |
- |
|
AN, n (%) |
4 (12.5) |
2 (16.7) |
2 (10) |
0.70 |
| Family history DM, n (%) | 20 (62.5) | 10 (83.3) | 10 (50) | 0.11 |
*Values are mean ± SD.
^ Significant P value = ≤ 0.05.
†BMI = weight in kilograms by the square of the height in meters.
CGC, Continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin’s lymphoma; GC, Glucocorticoids; BMI, Body-Mass Index; W/H ratio, waist to hip ratio; PAD, prednisone accumulative dose; AN, acanthosis nigricans; and DM, diabetes mellitus.